HC Wainwright Reiterates "Buy" Rating for Achieve Life Sciences (NASDAQ:ACHV)

Key Points

• HC Wainwright reiterated a "Buy" on Achieve Life Sciences with a $12.00 price target, implying about a 313% upside from the current price, while the MarketBeat consensus is a "Moderate Buy" with an average target of $15.50.
• Operationally, Achieve announced a manufacturing partnership with Adare Pharma to support cytisinicline production (a commercialization-positive step), but the company also posted a small Q4 EPS miss and faces a shareholder investigation by Johnson Fistel, creating near-term governance and downside risk.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $12.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price indicates a potential upside of 313.79% from the stock's current price.

Several other equities research analysts have also recently commented on the stock. Citizens Jmp started coverage on shares of Achieve Life Sciences in a research report on Tuesday, November 25th. They set a "market outperform" rating and a $19.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Achieve Life Sciences in a report on Monday, December 29th. Finally, Citigroup began coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They issued an "outperform" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Achieve Life Sciences presently has an average rating of "Moderate Buy" and an average target price of $15.50.

Achieve Life Sciences Price Performance

Shares of ACHV opened at $2.90 on Wednesday. The company has a quick ratio of 5.14, a current ratio of 5.14 and a debt-to-equity ratio of 0.26. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $6.03. The stock has a market capitalization of $154.38 million, a P/E ratio of -2.10 and a beta of 1.81. The company has a 50 day moving average of $4.49 and a 200-day moving average of $4.31.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.01). As a group, equities research analysts forecast that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Institutional Trading of Achieve Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences in the 1st quarter valued at about $32,000. Next Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at about $51,000. Sender Co & Partners Inc. acquired a new stake in Achieve Life Sciences in the 2nd quarter valued at about $56,000. OneDigital Investment Advisors LLC acquired a new stake in Achieve Life Sciences in the 3rd quarter valued at about $63,000. Finally, Magnolia Capital Advisors LLC bought a new position in Achieve Life Sciences during the fourth quarter worth about $64,000. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences News Summary

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: Announced a manufacturing partnership with U.S.-based Adare Pharma Solutions to support cytisinicline production — a constructive operational step toward commercialization that reduces manufacturing risk. Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
• Positive Sentiment: Unusual options activity — a large uptick in call buying (about 2,079 calls, ~175% above average) suggests some bullish/speculative positioning by traders which can support near-term demand for the equity.
• Neutral Sentiment: Company reported Q4 and full‑year 2025 results and held a conference call — management highlighted strategic advances in the cytisinicline program; the press release provides operational detail but no material upside guidance. Achieve Life Sciences Inc (ACHV) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
• Neutral Sentiment: Full earnings transcript now available for investors who want specifics on clinical timelines, manufacturing and commercialization execution risks. Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Reported EPS of ($0.28) vs. consensus ($0.27) — a small miss that can heighten short-term selling pressure in a low‑revenue, cash‑burn biotech where earnings misses amplify downside. Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (MarketBeat)
• Negative Sentiment: Johnson Fistel has opened a shareholder investigation into possible claims against Achieve executives — litigation risk/perception of governance problems can materially weigh on biotech stocks. Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
• Neutral Sentiment: Multiple short‑interest notices were posted but show inconsistent/zero values (reporting anomalies). The headlines about rising short interest may have contributed to sentiment, but the data appears unreliable — monitor official NASDAQ short‑interest releases for clarity.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.